SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No.2)
MedQuist Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, No Par Value
--------------------------------------------------------------------------------
(Title of Class of Securities)
584949101
--------------------------------------------------------------------------------
(CUSIP Number)
Stephen M. Kotran, Esq.
Sullivan & Cromwell
125 Broad Street
New York, New York 10004-2498
(212) 558-4000
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
July 31, 2000
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If a filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box [ ].
<PAGE>
--------------------------------------------------------------------------------
CUSIP NO. 584949101
--------------------------------------------------------------------------------
1. NAME OF REPORTING PERSON
Koninklijke Philips Electronics N.V.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
222531298
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [X]
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. SOURCE OF FUNDS
OO
--------------------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)
[ ]
--------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
The Netherlands
--------------------------------------------------------------------------------
7. SOLE VOTING POWER
NUMBER OF 24,400,086
SHARES --------------------------------------------------------------
BENEFICIALLY 8. SHARED VOTING POWER
OWNED BY 1,910,974
EACH --------------------------------------------------------------
REPORTING 9. SOLE DISPOSITIVE POWER
PERSON 24,400,086
WITH --------------------------------------------------------------
10. SHARED DISPOSITIVE POWER
1,910,974
--------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
26,311,060
--------------------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES
[ ]
--------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
64.6%
--------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON
CO
--------------------------------------------------------------------------------
-2-
<PAGE>
Item 1. Security and Issuer.
This Amendment No. 2 relates to the common stock, no par value (the
"Shares") of MedQuist Inc., a New Jersey Corporation. This Amendment No. 2
amends and supplements Item 5 of the Statement on Schedule 13D dated June 6,
2000 and Amendment No. 1 to such Schedule 13D dated July 28, 2000, previously
filed by Koninklijke Philips Electronics N.V., a corporation incorporated under
the laws of the Netherlands("Royal Philips"). Unless otherwise defined herein,
all capitalized terms used herein shall have the meanings ascribed to them in
the original Schedule 13D.
Item 5. Interest in Securities of Issuer.
Item 5 is hereby amended and supplemented as follows:
(a). As of the date hereof, Royal Philips beneficially owns 26,311,060
Shares, which constitutes approximately 64.6% of the outstanding Shares on a
fully diluted basis.
(b). Royal Philips has sole voting and dispositive power over
24,400,086 Shares of the Issuer and has shared voting and/or dispositive power
over 1,910,974 Shares of the Issuer.
(c). Between July 28, 2000 and August 1, 2000, Royal Philips purchased
1,000,000 Shares in open market transactions effected on the Nasdaq National
Market at prices ranging from $21.1875 to $21.8750 per Share as follows:
Date Shares Price
---- ------ -----
July 28, 2000 150,000 $21.2500
July 28, 2000 100,000 $21.3750
July 31, 2000 150,000 $21.3750
July 31, 2000 100,000 $21.1875
August 1, 2000 500,000 $21.8750
None of the persons listed in Schedule I beneficially owns or has the
right to acquire any Shares or has engaged in any transaction in the Shares in
the past 60 days.
-3-
<PAGE>
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: August 2, 2000
KONINKLIJKE PHILIPS ELECTRONICS N.V.
By: /s/ ADRI BAAN
---------------------------------
Name: Adri Baan
Title: Executive Vice President
Royal Philips Electronics.
By: /s/ JAN H.M. HOMMEN
---------------------------------
Name: Jan H. M. Hommen
Title: Executive Vice President
Royal Philips Electronics.
